Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amgen (NQ:AMGN)

296.47 +6.18 (+2.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amgen

< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Greenlight Capital Announces Q2 2025 Trades: New Positions in FLR and VSCO, Exit From VTRS
Greenlight Capital, led by David Einhorn, has disclosed its Q2 2025 13F filing trades. 
Via Benzinga
Is Eli Lilly Stock a Buy? Here's What the Market Isn't Pricing in Yet.
Viking Therapeutics' dual-formulation obesity drug could be the David to Lilly's Goliath. 
Via The Motley Fool
Topics Economy
Zevra Reported Its First-Ever Quarterly Profit. Why Shares Of The Top 6% Stock Crashed.
Zevra Therapeutics stock gapped down Wednesday after its first-ever quarterly profit missed even more bullish expectations. 
Via Investor's Business Daily
AMGN Q2 Deep Dive: Volume Growth, Pipeline Progress, and Guidance Raise Meet Investor Skepticism
Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q2 CY2025, with sales up 9.4% year on year to $9.18 billion. The company’s full-year revenue guidance of $35.5 billion at... 
Via StockStory
Topics Artificial Intelligence
Earnings Scheduled For August 5, 2025
 
Via Benzinga
Uncovering Potential: Amgen's Earnings Preview
 
Via Benzinga
Eli Lilly Shares Tumble After Disappointing Weight-Loss Pill Data
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a dramatic decline today, plummeting by more than 14% in early trading, wiping out approximately $98... 
Via MarketMinute
Eli Lilly Shares Tumble as Oral Weight-Loss Hope Falls Short of Lofty Expectations
Indianapolis, IN – Shares of pharmaceutical giant Eli Lilly and Company (NYSE: LLY) experienced a significant downturn, plummeting over 10% in premarket trading and continuing to slide throughout the... 
Via MarketMinute
Topics Economy
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen beat Q2 earnings and revenue expectations, raised 2025 guidance, and reported strong product sales growth across key therapies. 
Via Benzinga
Wall Street Recovers, Apple Rallies 6% On $100-Billion Gov Manufacturing Investment: What's Moving Markets Wednesday?
U.S. stocks rebounded sharply on Wednesday, fully erasing last Friday's losses, as upbeat corporate earnings and renewed investor optimism outweighed concerns over escalating trade tensions. 
Via Benzinga
RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program
Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue. 
Via Benzinga
Topics Lawsuit
Amgen Delivers Beat And Raise Quarter; Has Strong Late-Stage Pipeline
Amgen reported total revenue of $9.2 billion, topping the consensus of $8.9 billion, and non-GAAP earnings of $6.02 per share. 
Via Benzinga
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Via Investor Brand Network
Topics Government
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
EQNX::TICKER_START (NASDAQ:SNGX),(NASDAQ:FOLD),(NASDAQ:TNXP),(NASDAQ:CTOR),(NASDAQ:AMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Government
AMGEN INC (NASDAQ:AMGN) Shows Strong Technical Breakout Potential with High Setup Rating
AMGEN INC (AMGN) shows strong breakout potential with a Technical Rating of 7 and Setup Rating of 9, signaling bullish momentum and a tight consolidation pattern. 
Via Chartmill
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far. 
Via Benzinga
Topics Government World Trade
Amgen (AMGN) Q2 Profit Jumps 21%
Via The Motley Fool
Amgen’s (NASDAQ:AMGN) Q2: Beats On Revenue
Biotech company Amgen (NASDAQ:AMGN) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 9.4% year on year to $9.18 billion. The company expects the full year’s revenue... 
Via StockStory
Amgen Inc (NASDAQ:AMGN) Surpasses Q2 2025 Earnings Estimates Despite Muted Market Reaction
Amgen beats Q2 2025 earnings with $9.179B revenue and $6.02 EPS, but shares dip slightly as market reaction remains muted. CEO highlights growth in biosimilars and raised full-year guidance. 
Via Chartmill
Will Amgen, Already Above Its 50-Day Line, Break Out On This Earnings News?
Amgen crushed second-quarter forecasts late Tuesday. The news could push Amgen stock into a breakout. 
Via Investor's Business Daily
Stocks Drop As Trump Tariffs Fuel Inflation, Palantir Hits $400 Billion Value: What's Moving Market Tuesday?
Stocks slipped Tuesday as fresh economic data reignited stagflation fears on Wall Street, overshadowing a blowout quarter from Palantir Technologies Inc. 
Via Benzinga
Topics Economy Government
Stock Market Today: US Stock Futures Inch Higher, As Analysts Warn of Volatile August—AMD, Pfizer, Caterpillar In Focus
U.S. stock futures are inching higher on Tuesday, following a strong rally on Monday, with major benchmark indices in the green. 
Via Benzinga
Earnings To Watch: Amgen (AMGN) Reports Q2 Results Tomorrow
Via StockStory
Topics Artificial Intelligence World Trade
Nuclear Threats, Trump Fires Labor Statistics Chief, Fed Governor Resigns And More: This Week In Politics
 
Via Benzinga
Topics Economy Government
Trump Issues 60 Day Ultimatum To US Pharma Giants To Slash Drug Prices: 'If You Refuse To Step Up We Will...'
President Donald Trump has issued a 60-day ultimatum to 17 major pharmaceutical companies, demanding that they lower drug prices in the U.S. or face severe consequences. 
Via Benzinga
Topics Government
Trump Turns Up Heat On Big Pharma CEOs To Slash Drug Prices Within 60 Days — But Retail Traders Don't Flinch
Via Stocktwits
Topics Government
Soligenix Drug Matches FDA-Approved Amgen Therapy In Rare Disease Trial
Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast. 
Via Benzinga
2 Top Dividend Stocks to Buy Right Now and Hold Forever
Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors. 
Via The Motley Fool
Topics Intellectual Property
1 S&P 500 Stock with Competitive Advantages and 2 We Turn Down
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
56 57 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.